We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Comen Medical

Download Mobile App





New-Baseline Chest Imaging in Discharged COVID-19 Patients Could Help Identify Those at Highest Risk of Reinfection

By HospiMedica International staff writers
Posted on 31 Mar 2021
Print article
Illustration
Illustration
“New-baseline” imaging obtained from COVID-19 patients at the time of hospital discharge or clinical recovery may help clinicians to identify those at the highest risk of a relapse or reinfection from the SARS-CoV-2 virus or a secondary viral infection such as influenza.

Researchers from Keck School of Medicine of the University of Southern California (Los Angeles, CA, USA) have suggested that “new-baseline” imaging can be used to determine if readmissions are from relapse or reinfection of COVID-19, resolving COVID-19 or potentially a different viral infection (influenza), but also for long term sequela of COVID-19 lung infection.

COVID-19 relapse or reinfection may lead to readmission, which may cause a diagnostic challenge between recently infected patients and reinfections. Compounding this problem is the post-viral lung sequela that may be expected after COVID-19 pneumonia, similar to both Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). Although chest imaging may play a role in the diagnosis of primary SARS-CoV-2 infection, reinfection or relapse of COVID-19 will have similar imaging findings. According to the researchers, strategic use of imaging before discharge may be helpful in the subset of the population at the highest risk of a secondary viral infection such as influenza. Determining the residual abnormalities in post-discharge imaging can guide clinicians in the long-term management of patients for many years to come.

Pulmonary imaging abnormalities are highly likely to persistent in recovered COVID-19 patients. Early studies indicate that post-discharge/recovery radiologic imaging still reveals some abnormalities in recovered patients. The likelihood of residual pulmonary lesions after COVID-19 recovery will create additional challenges for imaging diagnosis between resolving pulmonary infection, reinfection with COVID-19 or a different virus (influenza). The use of a “new-baseline” imaging (preferably using CXR due to lower radiation) for high-risk patients can offer a snapshot of pulmonary findings either at the time of discharge or a follow-up examination. This could be especially important during the flu season, since influenza could cause similar clinical and radiological abnormalities as COVID-19.

Hence, the potential added value of a new-baseline chest radiography in patients who are recovered from SARS-CoV-2 infection cannot be overemphasized. The method of utilizing this new reference will assist the clinicians in facing possible future challenges. This may predict long-term pulmonary function, but also new-baseline chest imaging can guide clinicians in a better decision when encountering lung abnormalities on follow-up imaging of patients who once had COVID-19. Therefore, the researchers have recommended chest imaging at the time of discharge or shortly thereafter in patients at the highest risk of secondary viral infection and/or have comorbidities. This baseline imaging might also be of great value for continued surveillance of post-discharge COVID-19 patients. Determining the residual abnormalities in post-recovery imaging (specifically using CXRs as the main imaging tools due to its lower radiation, unless CT scans had been performed for other reasons) will guide clinicians in the long-term management of these patients for many years to come.

Related Links:
Keck School of Medicine


Print article

Channels

Business

view channel
Image: Respicardia’s remedē System (Photo courtesy of Respicardia, Inc.)

Zoll Medical Acquires CSA Systems Manufacturer Respicardia

ZOLL Medical Corporation (Chelmsford, MA, USA), an Asahi Kasei company, has acquired Respicardia, Inc. (Minnetonka, MN, USA), a provider of novel implantable neurostimulators for the treatment of moderate... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.